logo
Plus   Neg
Share
Email

Biogen, Sangamo Sign Deal To Develop Gene Therapies For Neurological Diseases

Biogen Inc. (BIIB) and Sangamo Therapeutics Inc. (SGMO), Thursday announced that they have reached a global collaboration deal to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular, and other neurological diseases.

The companies said that they will develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.

The companies will leverage Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.

"As a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance. We aim to develop and advance these programs forward to investigational new drug applications," said Alfred Sandrock Jr., M.D., Ph.D., Executive Vice President, Research and Development at Biogen.

SGMO closed Thursday's trading at $6.66, down $0.22 or 3.27%, on the Nasdaq. The stock, however, gained $2.60 or 38.93%, in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Missouri City, Texas-based Adco Trading Inc. has recalled about 142,740 units of candles citing fire and burn risks, according to the U.S. Consumer Product Safety Commission. The recall involves Sure Scents 2-1 Peaceful Stream/Moonlit Waves Candles. The affected items were manufactured in United States and sold exclusively at Dollar Tree stores across the country from July 2020 through September 2 United Parcel Service imposed temporary shipping restrictions on some big retailers such as Nike, Macy's and Gap, due to the increased demand for online orders and delivery in this holiday season, media reports said quoting an email statement issued by the delivery giant. An advisory panel to the Centers for Disease Control and Prevention has proposed that healthcare workers and long-term facility residents be given the first doses of the COVID-19 vaccine when it is cleared for public use in the U.S. The CDC's Advisory Committee on Immunization Practices met virtually on Tuesday and panel passed the proposal 13-1.
RELATED NEWS
Follow RTT